Glaucoma is the leading cause of irreversible blindness in the world. It is estimated that approximately 67 million people worldwide are affected with glaucoma and, of these, 6.7 million are bilaterally blind.l In Western countries, primary open-glaucoma (POAG) is by far the most common form of glaucoma? The four most important risk factors for the development of POAG include advanced age, black race, elevated intraocular pressure (lOP) and positive family history? The risk of developing glaucoma for individuals with a history of glaucoma among first-degree relatives is up to 8 times higher than the risk for the general population. [2] [3] [4] This heritable nature of glaucoma permits the use of molecular genetic techniques to study this important blinding disease.
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There are three main approaches to identifying a disease-causing gene ( Table 1) . The candidate gene approach is useful when there is a known gene whose function makes it a strong suspect. For example rhodopsin was a very reasonable candidate for retinitis pigmentosa and proved to be the disease causing gene in some cases.s Unfortunately there are too many potential candidate genes for POAG, including all the genes involved in the development, structure and function of the trabecular meshwork and optic nerve head.
A second approach is to identify patients who manifest the disease of interest and also have a chromosomal deletion or translocation; the break in the chromosome might be in or near the disease-causing gene. This technique has proved helpful for a variety of developmental glaucomas. Recently Nishimura et a/.6 discovered the forkhead transcription factor gene FKHL7 by studying the breakpoints in chromosome 6 of two children with primary congenital glaucoma and chromosomal trans locations. Mutations in this gene have been demonstrated to cause a variety of anterior segment abnormalities including Axenfeld anomaly and Rieger anomaly. 6, 7 In the absence of any other clues as to the location and nature of the gene causing a disease, the search typically begins by performing linkage analysis studies on large families affected with the disease. In this technique there is a search for co-segregation between a disease phenotype and polymorphic genetic markers. Unfortunately, POAG is not an ideal disease for linkage studies. Linkage analysis requires large numbers of living affected individuals. Because POAG is a late onset disease, the parents of affected individuals are almost always deceased, as are many of the siblings. Additionally, the children 
The proband and his family
As with all genetics studies, this story begins with a patient. The proband presented to the University of Iowa Department of Ophthalmology in 1986 requesting glaucoma filtration surgery. He was 28 years old and had been aware that he had glaucoma since age 16. At the time we first examined him he was using timolol maleate, dipivefrine HCl and pilocarpine gel. His lOPs were 24 mmHg in the right eye and 25 mmHg in the left. He supported the request for filtration surgery by presenting a simple pedigree that he had constructed. Half his relatives were affected by a form of glaucoma that had a very early age of onset, was resistant to medical therapy, was resistant to laser trabeculoplasty, and generally did well after filtration surgery. He ultimately had bilateral trabeculectomies with resultant excellent control of his lOP and stability of his optic nerves and visual fields.
In 1993, Johnson described this family in detailY The family was of German ancestry. Of 59 individuals in five generations who were at risk for the disease, 30 were affected ( Fig. 1 ). They had a POAG with a very early age of onset (mean 18 years) and very high lOPs (mean 45 mmHg). A sampling of the age of onset and lOPs of some of the more dramatic cases is shown in Table 2 . Eighteen (82%) of 22 living affected family members had Adapted with permission from Johnson et al. l3
These are some of the most striking examples from this pedigree.
undergone filtering surgery. Affected members of the family were usually myopic (mean refractive error -4.06 D) but otherwise had normal ocular anatomy. 1 3 It was felt that juvenile-onset POAG could serve as a model for the adult-onset disease because it shared the clinical phenotype, except for the following differences: a very early age of onset, a striking autosomal dominant inheritance pattern with high penetrance, and very high IOPs. 13 Otherwise, the diseases were identical; the iridocorneal angle was open and the trabecular meshwork was normal in appearance.
Linkage analysis DNA samples were obtained from 22 affected individuals and tested for linkage with 90 short tandem repeat polymorphism (STRP) markers scattered across the entire human genome. These markers, also called microsatellites, are areas of normal variability in the DNA sequence. There are thousands of these markers located on all chromosomes. These portions of the DNA can be amplified by polymerase chain reaction (PCR) and assayed to see whether one of the possible variations in DNA sequence (alleles) segregates with the affected phenotype.
In this family there was linkage between the affected status and markers on the long arm of chromosome 1 (lq21-q31) (Fig. 2) . 11 After this linkage was reported it was confirmed in populations in the United States 14 , 15 and throughout the world. 16 -1 8 The majority of large autosomal dominant juvenile-onset POAG families link to chromosome 1q. 1 9 A large family with both juvenile onset and adult-onset POAG was also found to link to chromosome 1q. 1 8 This locus on chromosome 1 was assigned the name GLC1A. 'GLC' stands for glaucoma, '1' stands for POAG, 'A' stands for the first linkage for this disease.
Fine mapping
Identifying the chromosomal locus was a major step in finding a gene for POAG. Unfortunately, within the interval described were hundreds of genes (mostly unidentified) and millions of base pairs. Characterising and screening all the genes in this interval for mutations would have been unrealistic. Therefore, further families were identified and more markers tested in order to reduce the linked interval to the smallest possible region. Sunden et al. 20 reported narrowing the interval to 3 centimorgans (cM) in 1996. A centimorgan is a unit of DNA length. One centimorgan is that length of DNA in which one would expect a 1 % chance of recombination in the offspring. Through a variety of techniques and assumptions the interval was finally narrowed to approximately 1 cM.9 Within this region were two known genes: APPTlLG1 and TXGP1.9 During the years that these family studies were in progress Drs Nguyen and Polansky were performing an independent and seemingly unrelated series of experiments. Their work was built upon the recognition that POAG can be induced in humans by the topical application of corticosteroids. In the laboratory they treated cultured trabecular meshwork cells with fairly high doses of dexamethasone. They then determined the changes in gene expression of the trabecular meshwork cells by comparing corticosteroid-treated cells with control cells. They discovered a protein that was markedly increased when the trabecular meshwork cells were exposed to corticosteroids. They named the protein trabecular meshwork inducible glucocorticoid receptor protein (TIGR).2 1 Because of the expression of this protein in the trabecular meshwork and its reponse to corticosteroids, the gene producing the TIGR protein was viewed as an attractive candidate gene for glaucoma. Stone et al. 9 discovered that the TIGR gene was in the interval containing GLC1A, further increasing the interest in this gene.
Cloning the gene
The TIGR gene was screened for mutations by a combination of single-strand conformational polymorphism analysis (SSCP) and direct sequencing. These techniques are designed to determine whether there are any alterations in the genetic coding sequence of the base pairs that make up the DNA. If a sequence variation is discovered that changes an amino acid in the resultant protein it is suspicious for being a disease causing mutation, especially if the sequence variation is seen much more commonly in patients than in unaffected individuals. The proband and his family were found to have a single base pair change that caused the amino acid histidine to be produced instead of tyrosine at codon 437 (TYR437HIS).9 Of eight families with juvenile-onset POAG, all were found to have mutations in this gene at GLC1A. 22 Mutations have now been found in a large number of patients in populations throughout the world?2-32
Nomenclature
The terminology of genetics terms can be confusing. GLC1A is the assigned name for the chromosomal linkage, as described above. Nguyen and Polansky called the gene TIGR for the reasons mentioned earlier. At approximately the same time that Nguyen and Polansky were describing TIGR, Kubota and co-workers described a protein in the photoreceptors of the retina that had some sequence homology to non-muscle myosin and olfactomedin; they called this protein myocilin?3 Myocilin and TIGR are identical. The international nomenclature committee, HUGO, has chosen the name myocilin for this protein. In this paper, GLC1A will refer to the chromosomal locus and myocilin to the gene and resultant protein.
Myocilin mutations in adult-onset POAG
In the first paper reporting that mutations in myocilin could cause juvenile-onset POAG, Stone et al.9 screened the DNA of adult-onset POAG patients as well. Myocilin mutations were found in 10 (4.4%) of 227 individuals In larger screen of 716 Midwestern American probands with adult-onset POAG, 33 patients (4.6%) were found to have one of 16 myocilin mutations?2 To determine whether the prevalence of mutations in myocilin was unique to the Midwestern American population, 1703 probands from five populations were evaluated. The study included primarily Caucasian patients from the Midwestern United States (Iowa), Canada and Australia; African-American patients from the United States (New York City); and Asian patients from Japan.27 A similar prevalence of myocilin mutations was found in these diverse populations, ranging from 2.6% to 4.3% (Table 3 ). 17 The fact that African-American patients have a similar percentage of myocilin mutations to Caucasian-Americans demonstrates that the increased prevalence of POAG among African-Americans is not caused by a higher prevalence of myocilin mutations?7
Mutations phenotypes
Of 16 mutations found in the screen of 716 Midwestern American probands, six were most prevalent (Table 4) . 22 The majority of mutations in myocilin cause a juvenile onset glaucoma with a mean age at diagnosis ranging from 20 to 37 years and mean peak lOPs as high as 44 mmHg. One mutation (GLN368STOP) stands out because, unlike the other mutations, it causes a typical adult-onset form of POAG with a mean age of onset of 59 years and a mean peak lOP of 30 mmHg -a phenotype indistinguishable from ordinary adult-onset POAG. 30% Fig. 3 . Genotypic evidence of a founder effect causing the Izigh prevalence of the GLN368STOP mutation. Twenty-seven probands and 35 sibs with the GLN368STOP mutation as well as 27 ethnically matched controls were genotyped at five markers closely flanking the myocilin gene. The fraction of subjects that shared a common allele of each marker is indicated. Reproduced with permission from Fingert et al. 27 There has even been a report of one patient with normal tension glaucoma who has been found to have the mutations held across the population, this family could account for tens of thousands of cases of POAG in the United States alone.
The structure and function of myocilin
Now that it is known that mutations in myocilin can cause adult-onset POAG, a great deal of attention has been turned to the function of myocilin. The myocilin protein is 57 kDa in size and contains three coding regions (exons) (Fig. 4) .27 Most of the mutations are found in exon 3, a part of myocilin with olfactomedin homology?7 Olfactomedin is a major component of the extracellular matrix of the olfactory neuroepithelium?4 Myocilin is expressed in the trabecular meshwork,2J and is in higher concentrations in glaucomatous eyes than in normal eyes. 35 As mentioned, the amount of myocilin in the trabecular meshwork can be increased with the application of corticosteroids. Besides the trabecular meshwork, myocilin is expressed in the ciliary body, retina, and 17 of 23 other organ system studied. The function of myocilin in health and disease is not known and has become the subject of intense research. Unlocking the role of myocilin should improve our understanding of the normal regulation of trabecular function. It should help us to understand how rop becomes elevated in glaucoma and thereby develop therapeutic interventions.
Other POAG loci
Since the description of GLC1A several other linkages for POAG have been described (Table 5 ). These have been discovered through linkage analysis studies in large families. All cause adult-onset POAG. The GLClE locus has been associated with a normal tension glaucoma phenotype. No genes have been identified at these loci to date.
Discussion
A linkage analysiS study in a single large family with juvenile-onset POAG led to the discovery of a locus on chromosome 1q (GLC1A) containing a gene that caused glaucoma in this family. 1 1 As other families from around the world were found to link to this site, it became apparent that this locus harboured a gene that caused glaucoma in the majority of families with autosomal dominant juvenile-onset disease. 1 5-IS After narrowing the disease-causing interval, candidate genes were evaluated and it was discovered that mutations in myocilin were responsible for the majority of families with autosomal dominant juvenile-onset POAG.9 More importantly, different mutations in this same gene were shown to cause some cases of typical adult-onset POAG.9 Myocilin mutations are found in 2.6--4.6% of adult-onset POAG patients in varying racial and ethnic groupS. 22, 27 One particular mutation (GLN368STOP) is especially interesting because it is the most prevalent mutation, because it has a phenotype indistinguishable from ordinary adult-onset POAG, and because most patients with this mutation around the world are related through a common founder. 22, 27 The structure of myocilin has been established and much is known about the expression of myocilin in various tissues?3,36 It is expressed in the trabecular meshwork and is inducible by the application of corticosteroids? 1 It is also found in many other tissues throughout the eye and has been detected in the majority of other organs tested?3,36 How myocilin functions remains a mystery.
An understanding of the molecular genetics of glaucoma holds much promise for the future of glaucoma diagnosis and management. Once the function of myocilin is determined it will provide pivotal information regarding the function of the trabecular meshwork. Understanding the physiology could lead to the discovery of other genes involved in trabecular function. Molecular genetic techniques will one day allow the earliest possible diagnosis of a population at risk for glaucoma, a group upon which we should target the limited screening resources, We can already determine which members of a family with myocilin mutations are at nearly 100% risk of developing the disease and which members are at no higher risk than the general population. At the present time population wide screening for myocilin mutations is not practical because this gene accounts for only about 3'l/o of POAG. However, as more mutations are discovered one can envision a day when a simple blood test or cheek swab will determine with high certainty the individuals at the highest risk for glaucoma.
Lastly we will, it is hoped, be able to develop better therapies for glaucoma from the knowledge of the molecular genetics. There is the ultimate prospect of gene replacement therapy, and indeed the technology exists to introduce genes into trabecular meshwork cells.39,40 Perhaps a more likely therapeutic application will be the development of drugs based on an understanding of the disease at a molecular level. One might develop a drug that inhibits the production of myocilin and therefore prevents the disease from developing. This drug might be highly effective and safe for glaucoma patients with myocilin mutations but may not be useful at all for patients with other forms of glaucoma.
